Articles From: L Brands To Present At The Deutsche Bank 22nd Annual Leveraged Finance Conference to La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference


2014/9/24
COLUMBUS, Ohio , Sept.
Sign-up for L Brands To Present At The Deutsche Bank 22nd Annual Leveraged Finance Conference investment picks
L-3 Communications Holdings, Inc. (NYSE:LLL) reported today preliminary unaudited financial results for the second quarter of 2014.
Sign-up for L-3 Announces Preliminary Second Quarter 2014 Results investment picks
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating if L-3 Communications Holdings Inc. (NYSE: LLL) committed securities violations by manipulating and misrepresenting financial data.
Sign-up for L-3 COMMUNICATIONS ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of L-3 Communications Holdings Inc. investment picks
2014/7/31
Former Attorney General of Louisiana, Charles C.
Sign-up for L-3 Communications Investigation Initiated by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates L-3 Communications Holdings Inc. Following Disclosure of Accounting Irregularities investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1144352&ProfileId=051205&sourceType=1 NEW ORLEANS, LA --
Sign-up for L-3 COMMUNICATIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against L-3 Communications Holdings Inc. - LLL investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against L-3 Communications Holdings Inc. (“L-3” or “Company”) (NYSE: LLL) and several officers and directors for acts taken during the period of April 25, 2013 to July 30, 2014 (the “Class Period”). Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of L-3.
Sign-up for L-3 Communications Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
L-3 Communications (NYSE:LLL) announced today that its Link Simulation & Training (L-3 Link) business has received an award from BAE Systems to develop the Hawk Oman Training System (HOTS). The training system, which is planned to achieve its ready-for-training milestone during the first quarter of 2017, will prepare Royal Air Force of Oman (RAFO) pilots to operate BAE Systems’ Hawk MK166 Advanced Jet Trainer aircraft.
Sign-up for L-3 Receives Award to Develop Hawk Oman Training System investment picks
L-3 Communications (NYSE:LLL) announced that in conjunction with its 2014 preliminary second quarter results announcement, the Company will host a conference call today at 8:30 a.m. ET that will be simultaneously broadcast over the Internet.
Sign-up for L-3 to Broadcast Second Quarter Conference Call Over the Internet – Note Time Change investment picks
2014/8/20
Sign-up for L-Brands posts 5% higher profit, lifts outlook investment picks
PITTSBURGH , Aug.
Sign-up for L.B. Foster Company Declares Quarterly Dividend investment picks
PITTSBURGH , July 29, 2014 /PRNewswire/ -- L.B. Foster Company (NASDAQ: FSTR) , today announced that it will broadcast a conference call to discuss its second quarter 2014 operating results on Monday, August 4, 2014 at 11:00am Eastern Time .
Sign-up for L.B. Foster Company To Report Second Quarter 2014 Operating Results On August 4, 2014 investment picks
L.B. Foster Reports Second Quarter Operating Results Canada NewsWire PITTSBURGH , Aug.
Sign-up for L.B. Foster Reports Second Quarter Operating Results investment picks
PITTSBURGH , Aug.
Sign-up for L.B. Foster Reports Second Quarter Operating Results investment picks
L.B. Foster To Present At D.A. Davidson E&C Conference Canada NewsWire PITTSBURGH , Sept.
Sign-up for L.B. Foster To Present At D.A. Davidson E&C Conference investment picks
PITTSBURGH , Sept.
Sign-up for L.B. Foster To Present At D.A. Davidson E&C Conference investment picks
2014/8/25
The Brand's Live Social Response Lab Will Empower Women To Be Their Own Beauty Expert And Create Red Carpet-Inspired Beauty Looks For Real Life Red Carpet Moments NEW YORK , Aug.
Sign-up for L'Oreal Paris Brings The Red Carpet To Women, In Real Time investment picks
Guidewire Software, Inc. (NYSE: GWRE) , a provider of software products to Property/Casualty (P/C) insurers, today announced that L’olivier Assurances , the French subsidiary of Admiral Group and an auto insurance provider, has selected Guidewire InsuranceSuite™ as its new platform for underwriting, policy administration, claims management, billing, rating, and client data management.
Sign-up for L’olivier Assurances Selects Guidewire Products for Underwriting, Policy Administration, Claims Management, and Billing investment picks
La Caisse de dépôt et placement du Québec invests $200 million in WSP as part of the acquisition of Parsons Brinckerhoff Canada NewsWire MONTRÉAL, Sept.
Sign-up for La Caisse de dépôt et placement du Québec invests $200 million in WSP as part of the acquisition of Parsons Brinckerhoff investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial.
Sign-up for La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH) investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
Sign-up for La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share.
Sign-up for La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.
Sign-up for La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
Sign-up for La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters’ option to purchase up to an additional 720,000 shares of common stock.
Sign-up for La Jolla Pharmaceutical Company Closes Offering of Common Stock investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons.
Sign-up for La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City.
Sign-up for La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: L Brands To Present At The Deutsche Bank 22nd Annual Leveraged Finance Conference to La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices